[Form 4] CME GROUP INC. Insider Trading Activity

Rhea-AI Filing Summary

Terrence A. Duffy, Chairman and CEO and a director of CME Group Inc. (CME), reported a purchase of 23,180 shares of Class A Common Stock on 09/15/2025 at a reported price of $258.83 per share. After the transaction he beneficially owns 90,804 shares. The Form 4 was signed on behalf of the reporting person by Margaret Austin Wright on 09/17/2025. No derivative transactions were reported.

Positive

• Reported insider purchase of 23,180 Class A shares by the CEO, increasing his direct beneficial ownership to 90,804 shares
• Clear disclosure of transaction date (09/15/2025), price ($258.83), and post-transaction ownership on a timely Form 4

Negative

• None.

Insights

Securities Analyst

TL;DR Insider purchase: CEO purchased 23,180 CME Class A shares, increasing direct beneficial ownership to 90,804 shares.

The Form 4 discloses a straightforward open-market acquisition by Terrence A. Duffy on 09/15/2025 at $258.83 per share. The report shows no option or other derivative activity. As filed, this is a routine insider purchase disclosure under Section 16 and provides transparency on the CEOs equity stake. The filing does not include additional context such as the source of funds or trading plan details.

Corporate Governance Expert

TL;DR Reporting is complete for the disclosed non-derivative purchase; no governance-related exceptions or amendments are evident.

The Form 4 identifies Duffy as both Chairman and CEO and confirms timely reporting with a 09/17/2025 signature date. The filing records a direct acquisition of Class A common stock and the updated beneficial ownership total. There are no disclosed indirect holdings, derivative positions, or amendments noted in the filing text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DUFFY TERRENCE A

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	09/15/2025		A		23,180	A	$258.83	90,804	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	By: Margaret Austin Wright For: Terrence A. Duffy	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Terrence A. Duffy report in the Form 4 for CME (CME)?

The filing reports a purchase of 23,180 Class A shares on 09/15/2025 at $258.83 per share, bringing his beneficial ownership to 90,804 shares.

Does the Form 4 show any derivative transactions for CME insider Terrence Duffy?

No. Table II for derivative securities contains no reported transactions in the provided filing.

What is Terrence Duffys relationship to CME as listed on the Form 4?

He is reported as both a Director and an Officer with the title Chairman and CEO.

When was the Form 4 signed and who signed it?

The form was signed on behalf of Terrence A. Duffy by Margaret Austin Wright on 09/17/2025.

What price per share was paid in the disclosed transaction?

The reported purchase price was $258.83 per share.